NewAmsterdam Pharma Company N.V. (NAMS)
NEUTRALFundamental
33
Price
$27.55
Market Cap
$3.14B
Part 1 · What the company is worth
Overview
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Balance Sheet & Liquidity
Revenue
$7M
Trailing 12 months (through 6/30/2026)
Net Income
$-260M
Trailing 12 months (through 6/30/2026)
Free Cash Flow
$-148M
Total Equity
$683M
Total Liabilities
$86M
Current Ratio
9.03
Interest Coverage
-
Debt/EBITDA
-
Earnings Per Share
Revenue & Net Income
Free Cash Flow
Income Breakdown
Historical statement
Margins over time
Debt over time
How heavy the debt is
Growth grid
Growth — Revenue
Fair Value Estimation
Fair Value
$30.63
Current Price
$27.55
Margin of Safety
+10.0%
Fair Value Range
$19.91 - $41.34
Estimation Methods
Valuation Metrics
P/E Ratio
-
ROE
-29.8%
P/B Ratio
5.08
P/FCF
-
Gross Margin
-
ROIC
-30.6%
Profitability Radar
Value Creation (Economic Moat)
ROIC
-30.6%
WACC
8.0%
ROIC − WACC
-38.6 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Fundamental Analysis Criteria
Passed (6)
- EPS shows upward trend
- Price CAGR 23.38%
- Debt/Equity ratio
- Current Ratio
- Low reliance on intangibles
- Analyst Consensus 91% Buy
Failed (11)
- ROIC -30.6%
- P/B Ratio 5.08
- Operating Margin -3432.2%
- Positive Free Cash Flow
- Return on Tangible Assets
- DCF valuation (Overvalued)
- ROE -38.3%
- Earnings Surprise avg -23.2%
- Share Dilution 25.6%
- Net Margin Trend -3644.2% vs -258.9%
- Piotroski F-Score 3/9
Unavailable (10)
- Gross Margin NaN%
- P/FCF NaN
- Dividend Payout NaN%
- CapEx intensity
- Interest Coverage
- Debt/EBITDA
- Price below Graham Number
- Revenue Growth 5Y (Finnhub)
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
Piotroski F-Score
Serious financial concerns
Earnings Quality
Low quality: investigate accounting
Share Dilution
Issuing new shares, diluting ownership
Governance
Executive Team
| Name | Title | Age |
|---|---|---|
| Dr. Michael Harvey Davidson FACC, Facp., M.D. | CEO, President & Executive Director | 69 |
| Dr. Johannes Jacob Pieter Kastelein FESC, M.D., Ph.D. | Founder, Chief Scientific Officer, Member of Executive Board & Director | 71 |
| Mr. Mayur Amrat Somaiya | Chief Financial Officer | 51 |
Part 2 · The price and when to enter
This part won't tell you whether the company is worth owning: it helps you choose when to buy it, once the fundamentals have convinced you. Inside: technical analysis, potential, historical drawdowns, gamma exposure.
Latest News
Recent headlines for NAMS, sourced from Markets Gazette.